Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Chemotherapy is often combined with PRTT to treat NETs of pancreatic or midgut origin (pNET/mNET) based on the principle of radiosensitization.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Pavlakis N
Authors: Pavlakis N, Ransom D, Wyld D, Sjoquist K, Asher R,
Keywords: Lutate, PRRT, chemotherapy, CAPTEM, NETs,
Introduction: PRRT with 177Lu-DOTATATE (LuTate) is effective in patients with metastatic or inoperable GEP-NETs.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: van der Zwan W
Authors: Van der Zwan W, Brabander T, Kam B, Teunissen J, Krenning E,
Keywords: Salvage, PRRT, Re-treatment, GEP-NET, Safety, Efficacy, 177Lu-DOTATATE,
Introduction: PRRT with 177Lu-DOTATATE (LuTate) is an effective treatment option in patients with metastatic or inoperable GEP-NETs.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: van der Zwan W
Authors: Van der Zwan W, Wyld D, Brabander T, Teunissen J, Kam B,
Keywords: PRRT, 177Lu-DOTATATE, Capecitabine, Xeloda, PFS, OS, Toxicity, GEP-NET, RCT, Randomized,
Introduction: LuTate is a treatment for well-differentiated NETs with adequate somatostatin receptor expression. Prognostic biomarkers in this population are lacking. Neutrophil-to-lymphocyte ratio (NLR) is prognostic in the majority of solid tumours but is reported to have less value in indolent well-differentiated NETs.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author:
Authors: Hayes A, Hosking E, Thomas D, Sjoquist K, Chan D,
Keywords: prognostic, biomarker, PRRT, LuTate,
#1825 The Effect of PRRT on Health-Related Quality of Life in NET Patients: A Prospective Study
Introduction: Neuroendocrine tumour (NET) patients experience poor health-related quality of life (HRQOL). Peptide receptor radionuclide therapy (PRRT) is a promising treatment option although its impact on HRQOL is not well understood.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author:
Authors: Patel D, Corsini N, Lawrie J, Nicholls D, Imogen R,
Keywords: PRRT, quality of life , Lutate,